CMA's Subsidy Advice Unit accepts Life Sciences £570m investment scheme for review
The Competition and Markets Authority's Subsidy Advice Unit (SAU) has accepted a request from the Office for Life Sciences (OLS) to review its proposed Life Sciences Large Investment Portfolio scheme. The £570m scheme, running from October 2025 to March 2030, will provide grants up to £130m to UK-registered companies investing over £250m in life sciences manufacturing or R&D. The SAU will evaluate the scheme's compliance with subsidy control requirements, with its report due by 2 October 2025. Third parties can submit comments until 5 September 2025. The scheme aims to expand UK life sciences manufacturing and commercial R&D capabilities in medicines, medical diagnostics, and MedTech products.